Novartis acquires Anthos Therapeutics in deal worth up to $3.1 billion, paying $925 million upfront

Blackstone Life Sciences and Anthos Therapeutics announced that Novartis has completed its acquisition of Anthos in a transaction valued at up to $3.1 billion. The deal includes a $925 million upfront payment, with additional payments tied to regulatory and commercial milestones. Anthos was founded in 2019 by Blackstone Life Sciences and Novartis to develop abelacimab, a novel Factor XI inhibitor currently in Phase 3 trials for atrial fibrillation and cancer-associated thrombosis.

Reinsurance Group of America Announces Board Change

Reinsurance Group of America, Incorporated (RGA) filed a Form 8-K with the SEC announcing that George Nichols III has informed the company he will not stand for re-election as a member of the board of directors at the upcoming annual meeting on May 21, 2025. The decision was not due to any dispute or disagreement with the company, its management, or the board regarding operations, policies, or practices.